Trials / Completed
CompletedNCT05831670
An Early Phase 2 Clinical Study of KSP-0243
An Early Phase 2 Clinical Study of KSP-0243 in Patients With Mild to Moderate Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to administer KSP-0243 or a placebo once daily after breakfast for 8 weeks in 100 patients with mild to moderate active ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KSP-0243 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2023-04-27
- Primary completion
- 2024-10-18
- Completion
- 2024-10-18
- First posted
- 2023-04-26
- Last updated
- 2025-03-17
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05831670. Inclusion in this directory is not an endorsement.